INGELHEIM, Germany--(BUSINESS WIRE)-- Boehringer Ingelheim today announced submission of applications to extend the indication for the use of tiotropium (Spiriva®) Respimat® to the treatment of asthma in adults aged 18 years and over.
"Our extensive studies have demonstrated that tiotropium Respimat® has the potential to be an effective new treatment option which can provide benefits to, and improve outcomes for, adult patients with asthma. Furthermore, we look forward to results from the paediatric UniTinA-asthma® Phase III studies which are anticipated to become available in 2014,4" said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim.
Help employers find you! Check out all the jobs and post your resume.
